(Q84342991)

English

Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial

scientific article published on 09 June 2012

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22683137%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22683137%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

0 references

type 2 diabetes

0 references

Francesco Dotta

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22683137%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

author name string

Baptist Gallwitz

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22683137%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Juan Guzman

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22683137%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Bruno Guerci

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22683137%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Rafael Simó

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22683137%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Bruce R Basson

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22683137%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Andreas Festa

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22683137%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Jacek Kiljański

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22683137%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Hélène Sapin

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22683137%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Michael Trautmann

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22683137%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Guntram Schernthaner

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22683137%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

language of work or name

0 references

publication date

9 June 2012

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22683137%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22683137%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

379

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22683137%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

9833

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22683137%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

2270-2278

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22683137%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960479-6

7 January 2021

based on heuristic

inferred from DOI database lookup

10-year follow-up of intensive glucose control in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960479-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960479-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960479-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of type 2 diabetes: new and future developments in treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960479-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960479-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960479-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960479-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960479-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960479-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960479-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960479-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Preservation of β-cell function: the key to diabetes prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960479-6

7 January 2021

based on heuristic

inferred from DOI database lookup

The effects of glucagon-like peptide-1 on the beta cell

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960479-6

7 January 2021

based on heuristic

inferred from DOI database lookup

The European Exenatide study of long-term exenatide vs. glimepiride for type 2 diabetes: rationale and patient characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960479-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960479-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960479-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960479-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Exenatide versus glibenclamide in patients with diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960479-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960479-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960479-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of pioglitazone and rosiglitazone combined with metformin on body weight in people with diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960479-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Type 2 diabetes: assessing the relative risks and benefits of glucose-lowering medications.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960479-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluating treatment algorithms for the management of patients with type 2 diabetes mellitus: a perspective on the definition of treatment success

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960479-6

7 January 2021

based on heuristic

inferred from DOI database lookup

The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960479-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960479-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960479-6

7 January 2021

based on heuristic

inferred from DOI database lookup

GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960479-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960479-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(12)60479-6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22683137%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22683137%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q84342991&oldid=1425534940"